You are using an outdated browser. Please
upgrade your browser to improve your experience.
Cancer mApp is the first iOS application that allows oncology professionals to have direct access to relevant clinical trial data on their iPad
Cancer mAPP
by Quatrian Inc.
What is it about?
Cancer mApp is the first iOS application that allows oncology professionals to have direct access to relevant clinical trial data on their iPad. Cancer mApp has summaries from hundreds of clinical trials conveniently organized and clearly presented in concise sets of summary slides. The database is fully searchable and allows you to send copies of the slides to colleagues or students. A great point of care tool for both clinicians and educators, Cancer mApp will allow you to access important evidence where and when you need it!
App Screenshots
App Store Description
Cancer mApp is the first iOS application that allows oncology professionals to have direct access to relevant clinical trial data on their iPad. Cancer mApp has summaries from hundreds of clinical trials conveniently organized and clearly presented in concise sets of summary slides. The database is fully searchable and allows you to send copies of the slides to colleagues or students. A great point of care tool for both clinicians and educators, Cancer mApp will allow you to access important evidence where and when you need it!
Disclaimer:
AppAdvice does not own this application and only provides images and links contained in the iTunes Search API, to help our users find the best apps to download. If you are the developer of this app and would like your information removed, please send a request to takedown@appadvice.com and your information will be removed.
AppAdvice does not own this application and only provides images and links contained in the iTunes Search API, to help our users find the best apps to download. If you are the developer of this app and would like your information removed, please send a request to takedown@appadvice.com and your information will be removed.
